Company
ASX:ALA
Arovella Therapeutics Ltd is a biotechnology company focused on developing its unique iNKT cell therapy platform to treat cancer. The company expects ALA-101 (CAR19-iNKT) cells to be effective against blood cancers that naturally produce CD19.
82 stories · page 4 of 5
“Liz is one of the rare individuals in the industry whose career spans the continuum of drug development, from leading early-stage research through to the commercialisation of final products. This is an exciting time in Arovella’s evolution
The sale of assets to Dapper Apps Pty Ltd will allow the company to focus on maturing its strategic investments. Operational and corporate overheads are also expected to be reduced to about $700,000 per annum from 1st July 2015.
